Amarin Announces Contractual Reminder of Optional Put to Holders of $15.1 million Principal Amount of Outstanding 3.50% Exchangeable Senior Notes Due 2032
December 16, 2016 16:31 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (the “Company”) announced today that it is providing a contractual reminder to holders of...
Pure EPA Vascepa® (icosapent ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Parameters in Statin-Treated Women with Persistent High Triglycerides
November 14, 2016 19:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an oral presentation at the American Heart Association Scientific...
Amarin to Present at the Jefferies 2016 London Healthcare Conference
November 11, 2016 10:26 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Reports Third Quarter 2016 Financial Results and Provides Update on Operations
November 03, 2016 05:30 ET
|
Amarin Corporation plc
Third Quarter Net Product Revenue Up 52% vs. Prior Year PeriodMaintaining Guidance on 2016 Net Product Revenue at $112-$125 Million;Anticipate Upper Half of RangeManagement to Host Conference Call at...
Amarin to Report Third Quarter 2016 Results and Host Conference Call on November 3, 2016
October 27, 2016 16:55 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Pure EPA Vascepa® Now Available in New, Smaller Half-Gram Capsule Size
October 25, 2016 07:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today the introduction of a smaller 0.5-gram capsule size for...
Amarin’s REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee
September 12, 2016 05:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that, as expected, the independent data monitoring committee (DMC) has...
Amarin to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
September 07, 2016 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa
August 31, 2016 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that randomization of patients into the REDUCE-IT cardiovascular outcomes study...
Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in May 2014 and November 2015
August 26, 2016 16:19 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin”), announced today that its wholly owned subsidiary, Corsicanto Limited, a...